Drug Trial Radar · NCT00966004
A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,139
Actual
Start
Jul 24, 2009
Primary completion
Feb 15, 2010
Study completion Feb 15, 2010
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Aug 26, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effect of YM178 in patients with overactive bladder for 12-week administration.
Conditions
- Urinary Bladder, Overactive
Interventions
YM178Drug
oral
PlaceboDrug
oral
tolterodineDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the mean number of micturitions per 24 hoursTime frame: Within a 12-week treatment period
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Chūbu, Japan
Site not named
Kantou, Japan
Site not named
Kinki, Japan
Site not named
Kyushu, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.